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Arteriovenous fistulas (AVFs) are usually used for vascular
access in the provision of hemodialysis, but AVFs have a
1-year patency rate of only about 60% owing to stenosis.
As the molecular mechanisms behind AVF neointimal
hyperplasia remain largely unknown, representative models
in transgenic mice could be useful to study this process at the
genetic level. Hence, we characterized neointimal lesion
formation in a model of AVF recently developed in the
mouse, where the common carotid artery was end-to-side
sutured to jugular vein in C57BL/6J mice. At the site of
anastomosis, arterial wall thickening was observed as early as
1 week after surgery (fourfold) and progressed to six- and
10-fold original thickness in carotid arteries after 2 and 3
weeks, respectively. The lumen of the carotid artery was
significantly narrowed owing to neointima hyperplasia, and
thrombosis was observed in the vein wall opposite to the
anastomosed artery. Histological and immunohistochemical
analyses revealed that 3-week neointimal lesions consisted of
abundant smooth muscle cells (alpha-actinþ ) and a small
number of membrane attack complex-1þ macrophages.
Furthermore, using chimeric mice receiving bone marrow
from transgenic mice expressing the LacZ gene in smooth
muscle (SM-LacZ), it was found that bone marrow stem cells
did not contribute to smooth muscle cell accumulation in
neointimal lesions of AVF arteries. Thus, this model, which
reproduces many of the features of human AVF, should prove
useful for our understanding of the mechanism of neointimal
formation and to evaluate the effects of drugs and gene
therapy on this disease.
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Hemodialysis vascular access dysfunction is one of the
most important causes for morbidity in hemodialysis
patients, who are approximately a quarter million
and growing at the rate of 5% per annum in the US.1
Concomitantly, it has been estimated that vascular
access dysfunction is responsible for more than 20%
of all hospitalizations in the end-stage renal disease popula-
tion.2 The native arteriovenous fistula (AVF) is frequently
used for vascular access in the provision of hemodialysis.
Unfortunately, AVFs have a 1-year patency rate of only about
60% and a 2-year patency of about 40%. The major cause for
AVF failure is neointimal hyperplasia leading to the
development of stenosis and subsequent thrombosis, but
the mechanisms of this neointimal formation remains poorly
understood.3,4
Peripheral AVFs have been described in small animal
such as rats and rabbits at the femoral or carotid levels.5,6
The ability to introduce transgenes or to disrupt endo-
genous gene expression has made the mouse an attractive
species for this model. However, the most widely used
AVF in mice is an aortocaval shunt, which predisposes
to major hemodynamic modifications leading to
cardiac failure.7,8 The use of a more peripheral AVF in
mice to reproduce native AVF for hemodialysis in
humans has not been described, to the best of our
knowledge.
Many studies have suggested that progenitor cells can
participate in the pathogenesis of vascular diseases in
models of allograft vasculopathy, postangioplasty restenosis,
and hyperlipidemia-induced atherosclerosis contributing
to smooth muscle cell (SMC) accumulation.9–16 On the
other hand, other reports have cast doubt on the pluripo-
tential of adult stem cells in vivo under physiological
conditions.17 Similarly, it was reported that bone marrow
stem cells might not contribute to the formation of mature
SMCs in allograft-induced neointimal lesions.15 It is
unknown whether progenitor cells play a role in the
neointima formation either in humans or in animal models
of AVF.
The purposes of the present study were to characterize the
neointima lesions that evolve after the creation of an AVF in
mice and to investigate the potential role of progenitor cells
in the neointima formation in this model.
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RESULTS
Neointimal formation in the artery and vein
AVF was performed in the mouse via end-to-side anasto-
mosis of the carotid artery and jugular vein, as illustrated by a
schematic picture and actual photograph in Figure 1a and d,
respectively. The overall perioperative mortality was 20% and
deaths were mainly related to either anesthesia or hemor-
rhage during recovery. All the AVFs analyzed in this study
were patent at the time of harvesting up to 3 weeks (vessel
patency at 3 weeks: 100%). The lumen of some AVFs started
to be occluded after 3 weeks and only one-third of vessels
were patent 4 weeks after surgery. Detailed hemodynamic
analyses are reported elsewhere.18 Briefly, blood flow was
increased more than six-fold in the RCCA proximal to the
AVF, but systemic blood pressure and heart rate remained
unchanged.18
We made a series of sections along the carotid artery.
Figure 2 shows the development of neointimal lesions 3
weeks after creation of the fistula at the different levels near
the anastomosis. At the proximal end of the artery, a normal
vessel structure, that is, 2–3 layers of cells in the vessel wall
(Figure 2a) was observed, associated with an increase in vessel
caliber in response to enhanced flow (see detailed description
in Castier et al.18). Neointimal lesions were observed in the
artery near the site of anastomosis (Figure 2b and c), and
maximal lesion formation was found at the level around the
suture (Figure 2d). A proportion of the lesions protruded
into the lumen of the jugular vein beyond the suture (Figure
2e).
Furthermore, the jugular vein of control animals had a
thin vessel wall (two or three cellular layers) surrounded by
perivascular tissue (Figure 2f), whereas the venous wall
opposite to the anastomosis revealed an increased thickness 3
weeks after AVF was established (Figure 2g and h).
Neointimal hyperplasia ranged from modest thickening of
the venous wall associated with a small thrombus (Figure 2g)
to more predominant hyperplasia extending in a papilliform
into a much larger thrombus (Figure 2h). Heterogeneity of
venous lesions was observed opposite to the anastomosis.
The initiation, development, and distribution of lesions in







Figure 1 | Schematic representation of AVF-associated lesion
formation in mice. A window was cut on the side of the jugular vein,
and the carotid artery was transected distally and sutured to the vein.
(a) Arrows represent direction of blood flow in the artery (A) and vein
(V). (b) Lesion formation (gray shading) occurred at the site of
anastomosis and on the vein wall opposite to the arterial opening. (c)
Lesion size progressed with time, encroaching on the lumen, and
protruding into the vein. Panel (d) shows a photograph of an AVF
after performing anastomosis, with black arrows indicating the
direction of blood flow. Note that the head of the mouse is at the left
and the heart at the right.
a b c 
d e
f g h
Figure 2 | Hematoxylin and eosin-stained sections of mouse
artery and vein at the site of AVF anastomosis. At 3 weeks after
opening of the AVF, vascular segments were fixed in situ in 4%
phosphate-buffered formaldehyde (pH 7.2), embedded in paraffin,
sectioned, and stained with hematoxylin–eosin. A series of sections
were cut in the artery at different levels approaching (a–e) the
anastomosis and (f–h) in the vein. Note that the lesion size increases
near (d) the anastomosis. (f) Shows a normal vein vessel wall before
surgery, whereas (g and h) represent vein sections 3 weeks after AVF.
Bar¼ 50mm.
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Figure 3 shows representative cross-sections with neointi-
ma hyperplasia progressing throughout the four time points.
Neointimal lesions were observed in the artery near the
suture at 1 week, and became larger at 2 and 3 weeks (Figure
3b, c and d). Figure 3e–h are representative photographs at
higher magnification corresponding to Figure 3a–d. Histo-
morphometric analysis showed that neointimal lesions were
strongly correlated with the time of fistula establishment
(P¼ 6.95 106). Lesion area (mm2) measured at the site of
the suture increased from 37 27273520 at 1 week to
105 51978676 at 3 weeks. In parallel, the lumen size of the
carotid artery reduced progressively with time after AVF
creation, such that 3 weeks after surgery the lumen was
almost closed by neointimal lesions (Figure 3 lower panel).
To verify whether the suture material could be at cause,
arterial remodeling was investigated in a group of sham
animals having a suture tied around the right carotid artery
during 4 weeks. We found no change in artery thickness and
no inflammatory cell infiltration in such arteries (data not
shown).
Cell composition
To study cell composition of neointimal lesions, sections were
probed with antibodies against macrophages, T cells, and
SMCs. Membrane attack complex-1 (MAC-1)þ monocytes/
macrophages were observed as early as 1 week after operation
(Figure 4b), whereas negative controls stained with normal
rat immunoglobulin (Figure 4a) displayed no positive
staining. The results shown in Figure 4c indicate abundant
macrophages in 2-week neointimal lesions, whereas fewer
MAC-1þ cells were present in the lesion 3 weeks after
creation of the AVF (Figure 4d). These cells were also
frequently found in the adventitia at all three time points,
particularly around the suture areas. T lymphocytes were
rarely found in the neointima, and were absent from the
adventitia (data not shown).
a-Actin is widely used as a marker of vascular SMCs,
although not all SMCs positively stain with antibody against
a-actin. Furthermore, immunoreactivity for a-actin is
reduced in rapidly replicating SMCs.19 Similar to findings
reported previously, we observed a very weak staining for a-
actin, if any, at 1 and 2 weeks after creation of the AVF
(Figure 4e and g). Nonspecific staining in negative controls
(Figure 4e) was minimal. Figure 4h demonstrates the
presence of abundant SMCs in the mature neointimal lesion
observed 3 weeks after creation of the AVF, indicating that
SMC accumulation at the site of anastomosis played an
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Figure 3 | Neointimal quantification in the AVF anastomosis.
Hematoxylin and eosin-stained sections were prepared as described
in Figure 2. Lesion area was measured microscopically as described in
the Materials and Methods. (a–d) Representative pictures of
anastomoses obtained 12 h, 1 week, 2 weeks, and 3 weeks after AVF
creation. Panels (e–h) are photographs at higher magnification
corresponding to panels (a–d). Bar¼ 50mm. The graph shows
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Figure 4 | Immunohistochemical staining demonstrates the pre-
sence of MAC-1þ mononuclear cells and SMCs in neointimal
lesions 3 weeks post-AVF. Frozen sections derived from the site of
anastomosis in arteries at (a and b) 1, (c) 2, and (d) 3 weeks post-AVF
were probed with normal rat immunoglobulin or with a rat
monoclonal antibody (CD11b/18; b–d) against MAC-1þ leukocytes.
For SMC staining, sections of arteries obtained (e and f) 1, (g) 2, and 3
weeks post-AVF were probed with (e) normal mouse serum or with
(f–h) a mouse monoclonal anti-a-actin antibody. A counterstaining
(blue) with hematoxylin was performed. Arrows indicate typical
positive cells. Bar¼ 10 mm. The graph shows mean7s.d. (n¼ 6/
group) (i).
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important role in neointimal lesion formation in this model.
Data summarized in Figure 4i indicates that a large
proportion of neointimal cells were SMCs, although MAC-
1þ cells were also present.
Cell origins in neointimal lesions
To determine the source of neointimal SMCs, chimeric mice
were used for AVF construction. We performed experiments
with C57/BL6J chimeric mice which had received SM-LacZ20
bone marrow cells after irradiation. When AVFs were
established in these irradiated mice (C57/BL6J/SM-LacZ
BM), which had only b-gal activity in bone marrow cells or
marrow-derived cells, no b-gal-positive cells were observed in
the neointimal lesions (Figure 5c). We also performed double
staining for a-actin and b-gal in sections of the neointimal
lesions from C57/BL6J/SM-LacZ BM chimeric mice with
bone marrow b-gal positivity. Data shown in Figure 5d
indicates the absence of double positive cells, although many
cells showed a-actinþ . As expected, b-galþ cells were
observed in the arterial wall of the SM-LacZ mouse (Figure
5a), whereas vessels derived from C57/BL6J mice were b-gal
negative (Figure 5b). These findings indicate that neointimal
cells were not derived from bone marrow cells.
DISCUSSION
In the present report, we have characterized a new model of
neointimal hyperplasia in the mouse that occurs at the site of
anastomosis connecting the carotid artery and the jugular
vein. This neointimal hyperplasia develops mainly around the
anastomosis and shows a rapid accumulation of SMCs.
Furthermore, we provide strong evidence that bone marrow
cells do not contribute to the deposition of SMCs in the
development of neointimal lesions in our model. To our
knowledge, this is the first time that a mouse model of
neointima hyperplasia in response to a ‘peripheral’ AVF has
been established. We believe that this model could be useful
for studying the pathogenesis of AVF-induced neointimal
formation, because the well-defined genetic systems of mice
make this species an attractive experimental model for
vascular biology research.21
The AVF is the vascular access of choice in the provision of
hemodialysis, and dysfunction and failure of AVFs necessitate
less desirable vascular accesses such as polytetrafluoroethy-
lene grafts and central venous catheters. Vascular access-
related morbidity severely impairs the welfare of patients
with end-stage renal disease and greatly amplifies the cost of
their medical care.1,2 In patients, the occurrence of uremia
may influence the neointmal formation in AVF. Although the
mice we used were not uremic, we suggest that our model
may be used to explore mechanisms of neointima formation
that contribute to the dysfunction and failure of AVFs used
for vascular access in patients with end-stage renal disease.
The mouse model of central (aortocaval) AVF incurs
major hemodynamic modifications leading to cardiac fail-
ure.7,8 In this respect, our model of a more peripheral AVF at
the cervical level is particularly valuable as it does not modify
the arterial blood pressure. Another chief advantage of the
murine model is the short period necessary (3 weeks) to
develop significant neointimal lesions, thereby facilitating
relatively short-term intervention or genetics studies. More-
over, to perform the AVF, we mimicked the suturing
technique which is used for constructing AVFs in clinical
practice. Although our model is technically demanding, with
experience we were able to achieve a surgical success rate
(fistula patent at 3 weeks) of about 90%.
We show that neointimal hyperplasia develops rapidly in
our model and is mainly located around the anastomosis, the
site most relevant to clinical states. In this AVF model, flow
rate increased sevenfold in the artery upstream of the
anastomosis, producing a marked artery enlargement as
previously reported.18 Although increased flow is known to
inhibit neointimal hyperplasia,22,23 altered biomechanical
stress at the site of anastomosis may have stimulated SMCs to
proliferate and accumulate in the intima.24 The turbulent
blood flow near the anastomosis, the surgical traumatism,
and the compliance mismatch between artery and vein are
believed to be factors that may have engendered this juxta-
anastomotic lesion.
The source of SMCs in neointimal lesions is a funda-
mental issue in understanding the pathogenetic interactions
of cells involved in the disease process. Recent reports
demonstrated that progenitor cells are present in the
adventitia25 and that bone marrow cells may contribute to
the accumulation of SMCs within neointimal lesions.11–13 In
the present report, we provide evidence that neointimal
SMCs of AVF anastomoses do not originate from bone
marrow stem cells, as identified directly by SMC SM22-




Figure 5 | Non-bone marrow origin of SMCs in neointimal lesions.
Bone marrow cells of SM-LacZ mice were transplanted into irradiated
wild-type mice 3 weeks before AVF surgery. Frozen sections were
stained for (a–c) X-gal or for both X-gal and (d) a-actin. (a and b)
Carotid arteries from SM-LacZ and wild-type mice, respectively. (c and
d) Sections from AVF artery anatomoses. Arrows indicate the luminal
surface of the vessels. Bar¼ 50mm.
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staining for a-actin in the early lesions, which progresses with
time and becomes strong in advanced lesions, suggesting a
maturation process of SMCs. However, we cannot exclude
the contribution of stem cells, for example, adventitial and
circulating SMC progenitors, to SMC accumulation in the
neointimal lesions of arteries with AVFs.
In summary, we have characterized a new mouse model
for AVF that shares some similarities with human AVFs. The
lesions consist mainly of SMCs which do not appear to be
derived from bone marrow stem cells. We believe that this
model could be useful for studying the pathogenesis of
neointimal formation for AVF-induced stenosis.
MATERIALS AND METHODS
Mice
All animal experiments were performed according to protocols
approved by the Institutional Committee for Use and Care of
Laboratory Animals. C57BL/6J mice were purchased from the
Charles River Laboratory (Les Oncins, France). Transgenic SM-LacZ
mice expressing b-gal under the control of the smooth muscle-
specific protein SM22 promoter have been described previously.26,27
The mice were maintained on a light/dark (12/12 h) cycle at 221C
receiving food and water ad libitum. The genetic constitution of all
mice used in the present study was C57BL/6.
Creation of arteriovenous fistula
AVFs were created in mice as recently described.18 Mice were
anesthetized by intraperitoneal injection of a mixture of ketamine
hydrochloride (0.20 mg/g) and xylazine (0.02 mg/g). After adequate
shaving and preparation of the neck skin, the mice were fixed in a
supine position with its neck extended. Each animal received 1 IU/g
of heparin at the onset of the procedure. The operation was
performed under a dissecting microscope (Nikon SMZ 1000).
Through a midline skin incision of the neck, the right common
carotid artery (RCCA) and external jugular vein (JV) were dissected
and exposed. The right cleidomastoid muscle was resected. All
branches of the JV were ligated (ethilon 10-0, Ethicon, Issy-Les-
Moulineau). The RCCA was clamped proximally, ligated just below
the carotid bifurcation with an 8-0 ethilon and transected. The JV
was clamped proximally and distally and a small venotomy was
performed in its middle part. Using microsurgical sutures (ethilon
11-0, Ethicon), an end-to-side RCCA/JV anastomosis was completed
with six interrupted sutures. Thereafter, the vascular clamps were
removed and fistula patency was verified. The operative field and the
vessel lumen were irrigated with a saline solution containing 100 IU/ml
of heparin. The skin was then closed with continuous stitches
using 6-0 vicryl. Operative time averaged 80 min, animals were kept
warm until complete recovery under a heating lamp, and 1.5 ml of
saline solution was injected subcutaneously at the end of the
procedure. The carotid–jugular fistula is schematically illustrated in
Figure 1a.
Tissue harvesting
At the time of killing, all the animals in this study were first
anesthetized and the fistula was dissected to assess its patency.
Thereafter, animals were killed by overdose of sodium pentobarbital
and tissues harvested for different analyses. For histological analysis,
mice were perfused briefly (1 min) at 80 mm Hg with 0.9% NaCl
solution via an abdominal aortic cannulation, and subsequently
perfusion fixed with 4% phosphate-buffered formaldehyde (pH 7.2)
for 15 min. To determine the time course of neointima formation,
we harvested the JV and RCCA adjacent to the anastomosis at
postoperative weeks 1, 2, and 3 (six animals per group). Samples
were fixed with 4% phosphate-buffered formaldehyde at 41C for at
least 24 h. For frozen section preparation, AVFs were harvested,
immediately frozen in liquid nitrogen, and stored at 801C.
Bone marrow transplantation
The procedure used for creating chimeric mice was similar to that
described previously.25,28 Briefly, donor mice were killed and the
femurs and tibias were removed aseptically. Marrow cavities were
flushed with Ca,Mg-free Hanks’ balanced salt solution (GIBCO-
BRL, Paisley) using a 25-gauge needle attached to a syringe. Single
cell suspensions were prepared by repeat pipetting, and the cell
preparations passed through a 120 mm nylon mesh filter to remove
particulate matter. Cells were washed twice in Hanks’ balanced salt
solution, counted using a hemocytometer, and resuspended at
3 107 cells/ml before transplantation. Six- to eight-week-old mice
received a lethal dose of whole body X-ray irradiation (950 Rads) as
described previously.15 The irradiated recipients received 1 107
bone marrow cells in 0.3 ml RPMI 1640 by tail vein injection. Six
animals were included for each group.
Histology and lesion quantification
After fixation, the samples were dehydrated in graded ethanol baths,
cleared in xylol, and embedded in paraffin.29 Histological sectioning
began at the arterial segment 1 mm above the anastomosis.
Routinely, 7 mm-thick sections were made throughout the dissected
fragments, stained with hematoxylin and eosin, and examined
microscopically (Zeiss, Go¨ttingen, Germany). The procedure for
lesion area measurement is similar to that described elsewhere.30
Using a transmission scanning microscope (LSM 510, Zeiss), vessels
were scanned, saved, and the lumen and perilesional tissue were
outlined using image analysis software. The lesion area was
determined by subtracting the area of the lumen from the area
enclosed by the internal elastic lamina. Lesion areas were measured
and recorded in square micrometers. When making vessel sections,
all sections were placed on slides and verified using a microscope.
The cross-section with greatest lesion size and six supplemental
cross-sections (three upstream, three downstream) situated at 28 mm
intervals were chosen for analysis.
Immunohistochemical staining
Serial 7 mm-thick frozen sections were cut from cryopreserved tissue
blocks and the procedure used in the present study for immuno-
histochemical staining was similar to that described previously.25,28
Briefly, macrophages were identified by application of a rat
monoclonal antibody (CD11b/18) against mouse MAC-1 leukocytes
(Pharmingen, San Jose, CA, USA) followed by biotinylated anti-rat
immunoglobulin secondary antibody (Dako-Glostrup, Denmark).
Smooth muscle cells were identified with a mouse monoclonal
antibody against a-actin labeled with phosphatase (Sigma, St Louis,
MO, USA) followed by Fast Red Tr/Naphthol AS-MX (Sigma). The
surface of positive-stained cells in the lesion was counted and
expressed as the percentage of total area.
b-Gal staining and double fluorescence labeling
The procedure for determining b-gal activity in sections was similar
to that described by Sanes et al.31 Briefly, sections were incubated at
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371C for 18 h in PBS supplemented with 1 mg/ml X-Gal (Sigma).32
For double staining of b-gal and SMC a-actin, we performed SMC
a-actin staining before b-gal staining. SMCs were identified with a
mouse monoclonal antibody against a-actin conjugated with
phosphotase (Sigma).
Statistical analysis
Statistical analyses were performed on a Macintosh computer with
StatView software using the Mann–Whitney U-test and analysis of
variance. Results are expressed as mean7s.d. A P-value o0.05 was
considered significant.
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